-
Je něco špatně v tomto záznamu ?
Evaluation of Soluble Urokinase Plasminogen Activator Receptor in COVID-19 Patients
S. Arientová, K. Matúšková, O. Bartoš, O. Beran, M. Holub
Status neindexováno Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články
Grantová podpora
MO1012
Czech Ministry of Defence
SVV 260636
Charles University
NLK
Free Medical Journals
od 2012
PubMed Central
od 2012
Europe PubMed Central
od 2012
ProQuest Central
od 2019-01-01
Open Access Digital Library
od 2012-01-01
Open Access Digital Library
od 2012-01-01
Health & Medicine (ProQuest)
od 2019-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2012
PubMed
39518479
DOI
10.3390/jcm13216340
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
Background/Objectives: This retrospective study analyzed soluble urokinase plasminogen activator receptor (suPAR) plasma levels alongside routine inflammatory markers, including the neutrophil-to-lymphocyte count ratio, C-reactive protein (CRP), interleukin-6 (IL-6), procalcitonin (PCT), and D-dimers in COVID-19 patients hospitalized during the Omicron wave of the pandemic. Methods: We measured plasma suPAR levels using a suPARnostic® Quick Triage kit. We divided COVID-19 patients into two groups based on the severity of SARS-CoV-2 infection according to the National Institutes of Health (NIH) criteria. The logistic regression analysis tested the predictive value of the biomarkers. Results: We evaluated 160 consecutive COVID-19 patients hospitalized between January and August 2022. The cohort exhibited a high incidence of comorbidities, with an in-hospital mortality rate of 5.6%. Upon admission, the median suPAR plasma levels were not significantly different between patients with mild COVID-19 (n = 110) and those with moderate/severe disease (n = 50), with 7.25 ng/mL and 7.55 ng/mL, respectively. We observed significant differences (p < 0.01) between the groups for CRP and IL-6 levels that were higher in moderate/severe disease than in mild infection. Additionally, suPAR plasma levels were above the normal range (0-2.00 ng/mL) in all patients, with a significant positive correlation identified between suPAR levels and serum IL-6, PCT, and creatinine levels. Conclusions: These findings indicate that COVID-19 during the Omicron wave is strongly associated with elevated suPAR levels; however, these levels do not directly correlate with the severity of SARS-CoV-2 infection.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25002304
- 003
- CZ-PrNML
- 005
- 20250123101844.0
- 007
- ta
- 008
- 250117s2024 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/jcm13216340 $2 doi
- 035 __
- $a (PubMed)39518479
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Arientová, Simona $u Department of Infectious Diseases, Military University Hospital Prague and First Faculty of Medicine of Charles University, 16902 Prague, Czech Republic
- 245 10
- $a Evaluation of Soluble Urokinase Plasminogen Activator Receptor in COVID-19 Patients / $c S. Arientová, K. Matúšková, O. Bartoš, O. Beran, M. Holub
- 520 9_
- $a Background/Objectives: This retrospective study analyzed soluble urokinase plasminogen activator receptor (suPAR) plasma levels alongside routine inflammatory markers, including the neutrophil-to-lymphocyte count ratio, C-reactive protein (CRP), interleukin-6 (IL-6), procalcitonin (PCT), and D-dimers in COVID-19 patients hospitalized during the Omicron wave of the pandemic. Methods: We measured plasma suPAR levels using a suPARnostic® Quick Triage kit. We divided COVID-19 patients into two groups based on the severity of SARS-CoV-2 infection according to the National Institutes of Health (NIH) criteria. The logistic regression analysis tested the predictive value of the biomarkers. Results: We evaluated 160 consecutive COVID-19 patients hospitalized between January and August 2022. The cohort exhibited a high incidence of comorbidities, with an in-hospital mortality rate of 5.6%. Upon admission, the median suPAR plasma levels were not significantly different between patients with mild COVID-19 (n = 110) and those with moderate/severe disease (n = 50), with 7.25 ng/mL and 7.55 ng/mL, respectively. We observed significant differences (p < 0.01) between the groups for CRP and IL-6 levels that were higher in moderate/severe disease than in mild infection. Additionally, suPAR plasma levels were above the normal range (0-2.00 ng/mL) in all patients, with a significant positive correlation identified between suPAR levels and serum IL-6, PCT, and creatinine levels. Conclusions: These findings indicate that COVID-19 during the Omicron wave is strongly associated with elevated suPAR levels; however, these levels do not directly correlate with the severity of SARS-CoV-2 infection.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Matúšková, Kateřina $u Department of Infectious Diseases, Military University Hospital Prague and First Faculty of Medicine of Charles University, 16902 Prague, Czech Republic
- 700 1_
- $a Bartoš, Oldřich $u Military Health Institute, Military Medical Agency, 16200 Prague, Czech Republic
- 700 1_
- $a Beran, Ondřej $u Department of Infectious Diseases, Military University Hospital Prague and First Faculty of Medicine of Charles University, 16902 Prague, Czech Republic
- 700 1_
- $a Holub, Michal $u Department of Infectious Diseases, Military University Hospital Prague and First Faculty of Medicine of Charles University, 16902 Prague, Czech Republic $u Ústřední Vojenská Nemocnice-Vojenská Fakultní Nemonice Praha, U Vojenské Nemocnice 1200, Praha 6-Břevnov, 16902 Prague, Czech Republic $1 https://orcid.org/0000000318942605 $7 xx0018615
- 773 0_
- $w MED00195462 $t Journal of clinical medicine $x 2077-0383 $g Roč. 13, č. 21 (2024)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39518479 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250117 $b ABA008
- 991 __
- $a 20250123101838 $b ABA008
- 999 __
- $a ok $b bmc $g 2254536 $s 1238307
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2024 $b 13 $c 21 $e 20241023 $i 2077-0383 $m Journal of clinical medicine $n J Clin Med $x MED00195462
- GRA __
- $a MO1012 $p Czech Ministry of Defence
- GRA __
- $a SVV 260636 $p Charles University
- LZP __
- $a Pubmed-20250117